Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Sorrento Therapeutics, Inc.
Sponsor:
Information provided by (Responsible Party):
Sorrento Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02064829
First received: February 14, 2014
Last updated: September 2, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2015
  Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)